We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Frontida BioPharm has launched its new Category 1 (CAT.ONE) in vitro testing and evaluation services to support development and regulatory approvals for abuse-deterrent formulations of pain management and Central Nervous System (CNS) targeted therapies.